United StatesÚltimas notícias

On this episode of Stock Movers with Alexis Christoforous: - Nuvalent (NUVL) shares are higher on news GSK agreed to buy Nuvalent for $10.6 billion, securing a US biotech firm developing treatments for lung cancer. - JM Smucker (SJM) shares are on the move after it posted fourth-quarter profits that beat Wall Street expectations as higher prices helped boost the packaged food company. - Vail Resorts (MTN) is dropping after the ski resort operator cut its net income guidance for the full year, attributing the reduction to "historically challenging" weather conditions in the western US. The guidance missed the average analyst estimate.

Airbus CEO Guillaume Faury comments on the planemaker's supply chain and orders during an interview with Bloomberg's Benedikt Kammel at the Berlin Aviation Summit.

Perma-Pipe International Holdings (NASDAQ:PPIH) reported an expansion in top-line revenue for the first quarter of fiscal year 2026, driven by sustained industrial demand across its primary geographic footprints, though near-term factory start-up friction and heightened regulatory compliance outlays compressed bottom-line margins.

Teleflex (NYSE:TFX) announced positive four-year follow-up data from its First-in-Human BIOMAG-I clinical trial, reinforcing the long-term safety and performance stability of its third-generation Freesolve Resorbable Magnesium Scaffold.

Vivakor (NASDAQ:VIVK) reported a narrower net loss and significantly stronger gross margins for the first quarter of 2026, signaling early progress in the company’s ongoing pivot toward its higher-margin midstream and logistics operations.

Cartesian Therapeutics (NASDAQ:RNAC) announced a strategic licensing agreement with WestGene Biopharma to co-develop innovative in vivo mRNA chimeric antigen receptor T-cell (CAR-T) therapies, marking a significant expansion of its clinical efforts to target severe autoimmune conditions.

BitFuFu (NASDAQ:FUFU) reported a 22.1% month-over-month increase in its unaudited Bitcoin production for May 2026, driven by a deliberate pivot toward its proprietary self-mining business and stabilized infrastructure conditions across its international footprint.

Aditxt (NASDAQ:ADTX) announced that its wholly owned subsidiary, Ignite Proteomics, has entered into a definitive business combination agreement with a strategic counterparty to transition the functional proteomics firm into an independent, publicly traded corporation.

Guneet Dhingra, head of US rates strategy at BNP Paribas, discusses the inflation risks he sees in markets and explains how the firm came to expect three rate hikes coming from the Federal Reserve.

OFS Credit Company (NASDAQ:OCCI) reported a contraction in its net asset value and a decline in quarterly investment income for its fiscal second quarter, driven by yield compression and weaker cash flow dynamics across its structured credit holdings.

TG Therapeutics (NASDAQ:TGTX) reported positive topline results from an early-stage clinical evaluation of a subcutaneous formulation of its flagship therapy, BRIUMVI, in patients with myasthenia gravis, marking a significant milestone in the company’s strategy to expand the drug's utility beyond its approved indication for multiple sclerosis.

RedHill Biopharma (NASDAQ:RDHL) announced that the U.S. Food and Drug Administration has granted rare pediatric disease designation to its investigational asset, opaganib, for the treatment of neuroblastoma, a type of cancer that primarily affects infants and young children.